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Systemic lupus erythematosus is a prototypical autoimmune disease characterized by the deregulation of T and B cells, tissue infil-
tration by mononuclear cells, tissue damage and the production of autoantibodies. There is a consensus that accelerated apoptosis 
of circulating lymphocytes and/or impaired clearance of apoptotic bodies may increase the amount of nuclear antigens presented to 
T lymphocytes. This process is accompanied by autoimmune responses that can lead to the development of lupus. The dysfunction 
of apoptosis may be a direct consequence of alterations in proteins/genes such as Fas, Bcl-2 and C1q. Increased expression of Fas 
antigen could intensify the exposure of hidden antigens. The overexpression of Bcl-2 protein might inhibit the removal of auto-
reactive cells, and the lack of C1q could impair the clearance of self-antigens. The complete knowledge of the role of apoptosis 
components in the etiopathogenesis of lupus could lead to the development of new therapies targeting the apoptotic threshold, which 
could result in a more specific and effective disease response compared to global immunosuppression. This review summarizes the 
role of each component of the apoptotic process in the pathogenesis of lupus.
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INTRODUCTION
Systemic lupus erythematosus (SLE) is a prototypical 
autoimmune disease characterized by deregulations of T and 
B cells causing the production of autoantibodies, immune-
complex deposition, tissue infiltration by mononuclear 
cells such as macrophages, and tissue damage.1-3 These 
immunological deviations can lead to a high morbidity and 
mortality, especially in childhood.1-3 The etiopathogenesis 
of SLE is not yet fully understood, but abnormalities of the 
apoptotic process are considered be related to the development 
of the disease.1,2 A delayed clearance of apoptotic cells was 
demonstrated in lupus patients.1,2,4,5 The impaired clearance 
of apoptotic debris by phagocytes can occur due to a specific 
abnormality in the receptors of these cells,6 the influence of 
a serum factor,7 reduced opsonization of apoptotic bodies6,7 
or a decreased number of phagocytic cells.8,9 Moreover, 
accelerated apoptosis of circulating cells is observed in SLE 
patients, and during this process specific lupus autoantigens, 
such as dsDNA, are exposed on surface blebs.1,3-5 The 
accelerated apoptosis may be a direct consequence of 
alterations in proteins/genes related to programmed cell death, 
such as Fas and Bcl-2. Increased expression of Fas antigen 
might intensify the exposure of hidden antigens, and the 
overexpression of Bcl-2 protein could inhibit the removal of 
auto-reactive cells1,2. These protein alterations might generate 
a pro-inflammatory status that overrides the mechanisms of 
tolerance, thus leading to lupus.1,2,10 This review summarizes 
the role of each component of the apoptotic process in the 
pathogenesis of lupus.
Apoptotic process
Apoptosis or programmed cell death is a genetically 
328
CLINICS 2010;65(3):327-33Apoptosis and SLE
Liphaus BL, Kiss MHB
conserved pathway and a regular feature in normal tissue 
homeostasis.5,11 Blood, epithelial and endothelial cells have 
especially high rates of turnover and must be promptly 
recognized for disposal.11 The main characteristics of the 
apoptotic phenomenon are membrane blebbing, the cleavage 
of DNA and the degradation of cellular components.5 
During apoptosis, intracytoplasmatic proteins are cleaved, 
and some of them are phosphorylated while others are 
redistributed.5 It has also been described that during 
apoptosis an increased amount of DNA shows abnormal 
methylation and GC content.12 The abnormal methylation 
of DNA can enhance its potential to activate murine and 
human B lymphocytes.12 It is believed that apoptotic 
cells are efficiently removed by reticuloendothelial cell 
system recognition of surface receptors such as scavenger 
receptor A (CD36) and the phosphatidilserine receptor 
(CD68).5,11 Some of these receptors also exert an influence 
on the cytokines generated by phagocytes.11 In addition 
to surface receptor recognition, a number of proteins, 
e.g., components of the complement system, could act as 
opsonins for phagocytes.13 Apoptosis is also essential for the 
establishment of tolerance, as demonstrated by Ferguson’s10 
studies on the eye, the prototypical immune-privileged 
organ. Programmed cell death might happen without 
being noticed by the immune system and consequently 
without inflammation.10 Nevertheless, inefficient disposal 
of dying cells or release of pro-inflammatory cytokines by 
lymphocytes during the engulfment of apoptotic bodies 
could lead to the activation of T cells.10 Therefore, self 
proteins or self-modified proteins could be presented to 
or could activate T cells, thus leading to autoimmunity.1,5 
However, peripheral tolerance mechanisms, such as 
regulatory T cells (Tregs), would restrain the autoimmune 
process. In addition, the apoptosis of lymphocytes during 
thymic selection would limit the presence of auto-reactive 
T lymphocytes in the periphery.4,5,10,14,15 It is now believed 
that dendritic cells, which are well-equipped to present self 
and non-self antigens to T cells via human leukocyte antigen 
(HLA) classes I and II, are also fundamental for establishing 
tolerance.1,5 The major histocompatibility complex (MHC) 
genotype determines which MHC molecules are available 
to the antigens and thus how well the antigens can be 
recognized by T cells. Particular MHC genes have been 
associated with an increased risk of an immune response 
to self-antigens and hence an increased risk of disease 
development, such as that observed in SLE patients.3,16,17
There is now enough evidence to consider genetic or 
immune disturbance of the apoptotic process as the main 
factor in the development of lupus.1,14 From this perspective, 
accelerated apoptosis of circulating lymphocytes and/or 
impaired clearance of apoptotic cells in patients with lupus 
might lead to an increased amount of intact nuclear antigens 
or modified proteins in the extra-cellular tissue. These self-
antigens could be presented by dendritic cells to peripheral 
auto-reactive T lymphocytes, thus driving an autoimmune 
response.10 Additionally, B cells producing autoantibodies 
could avoid apoptosis, thereby maintaining their activated 
state.1,4 
It has been observed that lupus-specific autoantigens, 
including dsDNA, are exposed on the surface of apoptotic 
cells.1,5 Casciola-Rosen et al.18 demonstrated that UVB-
irradiated keratinocytes undergo apoptosis and that lupus 
autoantigens such as 60-Kd Ro and La are strikingly 
redistributed, becoming concentrated on surface blebs. 
Additionally, Emlen et al.19 and Courtney et al.20 observed 
increased numbers of circulating apoptotic leukocytes and 
lymphocytes in SLE patients. Another study showed that 
lymphocytes from lupus patients undergo apoptosis at a 
significantly greater rate than lymphocytes from healthy 
controls.21 Moreover, adult patients with lupus present 
accelerated apoptosis of monocytes and consequently a 
decreased survival of these cells.8,9 Kaplan et al.9 showed 
that the autologous monocyte death is mediated by apoptotic 
ligands, i.e., TRAIL, TWEAK and FasL. These observations 
suggest that both an increase of circulating apoptotic bodies 
and a decreased clearance of apoptotic debris by phagocytic 
cells might occur in SLE pathogenesis. 
The decreased function of phagocytic cells can also 
occur as a consequence of specific abnormalities in 
membrane receptors.11 Mice deficient in factors such 
as DNaseI, SAP, C1q, IgM and Mer, all of which are 
required for proper binding and clearance of apoptotic 
cells, spontaneously develop anti-nucleosome antibodies 
and glomerulonephritis.22 However, the former hypothesis 
was not supported by Bijl et al.,6 who observed similar 
expression of CD14, CD18, CD36 or CD51/61 on 
monocytes from lupus patients and from healthy subjects. 
These authors concluded that the reduced uptake of 
apoptotic cells by monocyte-derived macrophages from 
patients with SLE was not an intrinsic defect, but was serum-
dependent and associated with decreased levels of C1q, C4 
and C3.6 
From this point of view, the delayed clearance of 
apoptotic cells may provide self-antigens with access to 
antigen-presenting cells from which they were normally 
excluded. Most importantly, impaired clearance of apoptotic 
lymphocytes by macrophages has been demonstrated in both 
lupus-prone mice and patients.23,24 In addition, accumulation 
of apoptotic debris in lymph node germinal centers and 
an increased proportion of apoptotic Fas-expressing cells 
among bone marrow CD34+ hematopoietic progenitor cells 
were observed in SLE patients.25,26 The presence of uncleared 
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apoptotic material at sites of B-cell and T-cell selection may 
explain the loss of tolerance observed in these patients. 
Although apoptosis is a well-accepted factor for lupus 
development, it is not well established how the observed 
abnormalities trigger autoimmunity.
Fas and Bcl-2 proteins
Apoptosis is induced by a range of stimuli that activate 
two major cell death signaling pathways: the intrinsic 
pathway controlled by Bcl-2 family members and the 
extrinsic cell death pathway controlled by death receptors of 
the tumor necrosis factor receptor super-family.5
Apoptosis depends both on coordinated action between 
proteins inducing and inhibiting the process and on the 
activation of caspases that cleave the DNA.2,4,5 Furthermore, 
the relationship between the inducers and inhibitors of 
apoptosis may differ according to cell type. Disturbance of 
the expression of Fas, FasL, Bcl-2, Bim, Bcl-x, Mcl-1 and 
TACI could lead to the accumulation of apoptotic bodies.2,5,10 
Fas receptor and Bcl-2 protein have significant roles in 
lymphocyte selection, proliferation, survival and death.4,5
It is well-known that Fas-FasL interactions play an 
essential role in maintaining the homeostasis of the immune 
system.5 Fas (APO1/CD95) is an apoptosis-promoting cell 
surface receptor.5 It was first described in MRL/Ipr mice 
with a Fas gene mutation that prevented cell death. These 
mice developed a lymphoproliferative syndrome with 
features resembling human SLE.27 In addition, Suda et al.28 
showed that the murine lupus model MRL/gld presented a 
mutation at the FasL gene that prevented its expression. 
Increased lymphocyte Fas expression has been reported 
in patients with lupus.20,29-31 These studies found an 
increased expression of Fas on T and B lymphocytes from 
SLE patients and demonstrated a positive correlation with 
disease activity.29,31 Amasaki et al.30 observed increased 
expression of Fas in both CD4+ and CD8+ T-cell subtypes 
from SLE patients when compared to healthy controls. 
Additionally, Suzuki et al.32 observed high expression of 
FasL on lymphocytes from lupus patients. Soluble Fas (sFas) 
is a variant of the Fas receptor lacking the transmembrane 
region. It has been detected in human sera and was found 
to inhibit apoptosis induced by Fas protein.5 This soluble 
form of Fas causes splenomegaly and lymphadenopathy 
when injected into normal mice.20,33 Patients with SLE 
show increased levels of sFas when compared to healthy 
controls, and a positive correlation was also shown between 
sFas, leucopenia and anti-dsDNA antibodies.19,33,34 Together, 
these data suggest that high expression of Fas antigen 
on lymphocytes might lead to rapid cell turnover and to 
increased exposure of the immune system to autoantigens, 
thus leading to autoimmune disease.1,4 Additionally, because 
sFas can suppress Fas-mediated apoptosis, it has been 
suggested that sFas can help autoreactive thymocytes to 
escape negative selection.34 However, the positive correlation 
between sFas level and dsDNA antibodies suggests a pro- 
rather than an anti-apoptotic activity of sFas. Telegina et 
al.34 described that the oligomeric form of sFas stimulates 
apoptotic cell death, and that its levels are increased in 
sera from lupus patients when compared to the monomeric 
form. The exact function of sFas in the pathogenesis of SLE 
remains to be established. 
Although Fas-mediated lymphocyte apoptosis is a 
well-known source of autoantigens, gene abnormalities in 
other cell death pathways cannot be ruled out. Habib et al.35 
showed that T lymphocytes from lupus patients presented 
enhanced apoptosis in the presence of TNFa, independent 
of the Fas-FasL pathway. Pyrovolaki et al.26 demonstrated 
that the proportion of CD40-expressing CD34+ cells was 
significantly increased in SLE patients. These authors 
also observed a cooperative interaction of CD40 and Fas 
pathways in the promotion of apoptosis of CD34+ cells.26
The Bcl-2 protein inhibits multiple forms of apoptosis 
and plays a pivotal role in the regulation of apoptosis in 
several cell types, including human B and T cells.5 Bcl-2 
expression is tightly regulated in T lymphocytes, monocytes 
and neutrophils, which suggests a critical role of this 
protein in cell death.5,36 Overexpression of Bcl-2 protein 
in transgenic mice protects B cells against cell death and 
promotes the development of a lupus-like autoimmune 
syndrome with nephritis and autoantibodies such as anti-
dsDNA and anti-Sm.37 
The expression of the apoptosis-inhibiting protein 
Bcl-2 in freshly isolated lymphocytes from lupus patients 
has been a controversial matter. Some investigations have 
shown increased Bcl-2 expression in T cells but not in B 
cells, while others demonstrated unaltered Bcl-2 quantities 
in unfractionated lymphocytes from adults with SLE.22,38,39 
Miret et al.40 observed high levels of serum Bcl-2 in patients 
with active SLE when compared to patients with the inactive 
disease. Increased expression of Bcl-2 in lymphocytes might 
inhibit the removal of auto-reactive cells that could remain 
viable and thus be selected for further differentiation.
Studies involving juvenile-onset SLE patients are rare. 
Falcini et al.41 observed an increased expression of Bcl-2 
protein in T lymphocytes. Additionally, Liphaus et al. showed 
an increased expression of Fas protein in CD3+, CD4+, 
CD8+ and CD19+ cells in juvenile-onset SLE patients when 
compared to healthy controls and to patients with juvenile 
rheumatoid arthritis or juvenile dermatomyositis.42 Bcl-2 
expression was also higher in T lymphocytes from juvenile-
SLE patients, but not in B cells, when compared to healthy 
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individuals.42 In addition, there was a positive correlation 
between Fas and Bcl-2 expression in B cells and disease 
activity; different profiles of these proteins were demonstrated 
in patients with active and inactive disease.43 
The study of abnormalities in the expression of 
proteins related to apoptosis can be important not only for 
understanding the etiopathogenesis of lupus but also for 
contributing to its therapy.3,11,14 Seki et al.44 observed that 
SLE patients who are resistant to steroid therapy presented 
increased expression of Bcl-2 in CD8+ T cells. This study 
provided an important strategy for stratifying patients for 
therapeutic intervention.
At present, the role of apoptosis in the pathogenesis of 
SLE is thought to primarily consist of accelerated apoptosis 
and impaired clearance of apoptotic bodies, which lead 
to increased amounts of antigens that can be presented to 
immunocompetent cells. There is substantive evidence 
in the literature implicating apoptotic debris in disease 
development. Apoptosis is mediated by many proteins, 
although the role of each component and their interactions 
are not fully established. Increased expression of Fas antigen 
has been documented and explained, but the increased 
expression of Bcl-2 protein still requires more interpretation. 
One possible reason for this could be that the elevation of 
Fas is quantitatively or qualitatively more important than 
that of Bcl-2, or that other factors could play a role in the 
activation of Fas or Bcl-2 proteins.
C1q deficiency 
Although homozygous complement deficiencies are 
rare conditions, lupus develops in more than 90% of C1q-
deficient individuals, and complement deficiencies are the 
strongest single genetic risk factor for the development of 
this disease.3,13,45-47 C1q-deficient patients tend to present the 
disease at a young age, and there is no female predominance, 
which supports the notion that no other genetic factor is 
involved.46,47 This strong association invokes the role of 
complement in physiological waste disposal, particularly 
in the processing and clearance of dying cells and immune 
complexes.13,47-49 It has been demonstrated that C1q binds to 
surface blebs of apoptotic human keratinocytes and that C1q 
is essential for the proper clearance of apoptotic cells, which 
are considered as the primary source of self antigens that 
break tolerance during SLE development.6,45,46,48-50 Another 
hypothesis proposes that complement also plays a role in 
the activation of B and T lymphocytes, and that complement 
deficiency can cause autoantibody production by impairing 
the normal mechanisms of tolerance.49,51-53 It was also shown 
that C1q is a potent modulator of dendritic cells, resulting in 
an impaired capacity for cytokine production, down-regulation 
of costimulatory molecules and a limited T-cell response.54 In 
addition, the binding of C1q results in complement activation, 
causing opsonization of apoptotic cells with C4b and C3b. 
This opsonization will further accelerate their uptake by 
phagocytes and contribute to additional anti-inflammatory 
responses.49 The former observations can explain why other 
complement component deficiencies have also been associated 
with lupus.13 Botto et al.55 demonstrated impaired clearance of 
apoptotic cells and development of severe glomerulonephritis 
and multiple autoantibodies in C1q-knockout mice. The 
important role of complement in apoptosis is further 
supported by data showing that the addition of complement 
components to an in vitro phagocytosis assay using human 
macrophages and apoptotic lymphocytes generated more 
than a threefold increase in the uptake of apoptotic cells.53 
This finding is corroborated by the report of the reduced 
clearance of immune-complex in the spleen of a patient with 
C2 deficiency and lupus. The impaired uptake was restored by 
normalizing C2 levels with the use of fresh-frozen plasma.56 
Another study demonstrated that IgM binds apoptotic cells 
and recruits C1q and C3b, contributing to their clearance.57 
Although there is a strong link between C1q and SLE, most 
patients do not have a primary deficiency of complement. 
Low levels of C1q are often due to the consumption of early 
complement components associated with the presence of anti-
C1q antibodies.50,54,58 Bigler et al.59 demonstrated that anti-C1q 
antibodies from SLE patients specifically target C1q bound 
on early apoptotic cells, which might alter the clearance of 
these dead cells and enhance the proinflammatory immune 
response. The presence of anti-C1q antibodies has also been 
tightly linked to the occurrence of severe lupus nephritis, 
although there is still some controversy.50,58 Collectively, 
these data show that the early components of the classical 
complement pathway have a critical role in waste disposal of 
apoptotic cells and a crucial protective activity against lupus 
development. 
The presence of anti-C1q antibodies may suggest the 
modification of C1q, either genetically or by the apoptotic 
environment. The binding of C1q to anti-C1q will result 
in complement activation and tissue damage. Given this 
rationale, C1q deficiency should protect against lupus; 
nevertheless, in reality, C1q deficiency is strongly related to 
the development of the disease. Thus, C1q deficiency may 
be an important human model for better understanding of the 
impaired clearance of apoptotic bodies.
Autoantibodies are considered a hallmark in lupus 
patients. All of the mechanisms described above suggest 
the presence of hidden or modified antigens that could elicit 
autoantibodies. However, some questions still remain to be 
answered. For example, autoantibodies also occur in healthy 
people and in other autoimmune diseases, such as juvenile 
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rheumatoid arthritis and dermatomyositis, where they are 
not considered pathogenic. Autoantibodies are also able to 
opsonize dead cells, facilitating their ingestion by professional 
phagocytes. Investigation into the above questions may clarify 
the role of autoantibodies in the pathogenesis of lupus and 
introduce a new branch of research.
CONCLUSION
Taken together, these findings suggest that deregulations 
of apoptotic phenomena and deficiencies of early 
components in the complement pathway have a critical 
role in the increased exposure of self-antigens. This is 
currently considered the main hypothesized mechanism 
for the development of lupus. The discovery of new factors 
involved in the apoptosis process and identification of 
potentially different roles for proteins already known to be 
related to SLE pathogenesis are challenges that still need to 
be addressed.
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